<?xml version='1.0' encoding='utf-8'?>
<document id="19130187"><sentence text="Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 2: clinical trial results." /><sentence text="To compare results of population PK analyses obtained with a full empirical design (FD) and an optimal sparse design (MD) in a Drug-Drug Interaction (DDI) study aiming to evaluate the potential CYP3A4 inhibitory effect of a drug in development, SX, on a reference substrate, midazolam (MDZ)"><entity charOffset="275-284" id="DDI-PubMed.19130187.s2.e0" text="midazolam" /></sentence><sentence text=" Secondary aim was to evaluate the interaction of SX on MDZ in the in vivo study" /><sentence text=" Methods To compare designs, real data were analysed by population PK modelling technique using either FD or MD with NONMEM FOCEI for SX and with NONMEM FOCEI and MONOLIX SAEM for MDZ" /><sentence text=" When applicable a Wald test was performed to compare model parameter estimates, such as apparent clearance (CL/F), across designs" /><sentence text=" To conclude on the potential interaction of SX on MDZ PK, a Student paired test was applied to compare the individual PK parameters (i" /><sentence text="e" /><sentence text=" log(AUC) and log(C(max))) obtained either by a non-compartmental approach (NCA) using FD or from empirical Bayes estimates (EBE) obtained after fitting the model separately on each treatment group using either FD or MD"><entity charOffset="125-128" id="DDI-PubMed.19130187.s8.e0" text="EBE" /></sentence><sentence text="" /><sentence text="For SX, whatever the design, CL/F was well estimated and no statistical differences were found between CL/F estimated values obtained with FD (CL/F = 8"><entity charOffset="146-147" id="DDI-PubMed.19130187.s10.e0" text="F" /><entity charOffset="0-0" id="DDI-PubMed.19130187.s10.e1" text="F" /><entity charOffset="32-32" id="DDI-PubMed.19130187.s10.e2" text="F" /><entity charOffset="106-106" id="DDI-PubMed.19130187.s10.e3" text="F" /><entity charOffset="139-139" id="DDI-PubMed.19130187.s10.e4" text="F" /><pair ddi="false" e1="DDI-PubMed.19130187.s10.e1" e2="DDI-PubMed.19130187.s10.e1" /><pair ddi="false" e1="DDI-PubMed.19130187.s10.e1" e2="DDI-PubMed.19130187.s10.e2" /><pair ddi="false" e1="DDI-PubMed.19130187.s10.e1" e2="DDI-PubMed.19130187.s10.e3" /><pair ddi="false" e1="DDI-PubMed.19130187.s10.e1" e2="DDI-PubMed.19130187.s10.e4" /><pair ddi="false" e1="DDI-PubMed.19130187.s10.e1" e2="DDI-PubMed.19130187.s10.e0" /><pair ddi="false" e1="DDI-PubMed.19130187.s10.e2" e2="DDI-PubMed.19130187.s10.e2" /><pair ddi="false" e1="DDI-PubMed.19130187.s10.e2" e2="DDI-PubMed.19130187.s10.e3" /><pair ddi="false" e1="DDI-PubMed.19130187.s10.e2" e2="DDI-PubMed.19130187.s10.e4" /><pair ddi="false" e1="DDI-PubMed.19130187.s10.e2" e2="DDI-PubMed.19130187.s10.e0" /><pair ddi="false" e1="DDI-PubMed.19130187.s10.e3" e2="DDI-PubMed.19130187.s10.e3" /><pair ddi="false" e1="DDI-PubMed.19130187.s10.e3" e2="DDI-PubMed.19130187.s10.e4" /><pair ddi="false" e1="DDI-PubMed.19130187.s10.e3" e2="DDI-PubMed.19130187.s10.e0" /><pair ddi="false" e1="DDI-PubMed.19130187.s10.e4" e2="DDI-PubMed.19130187.s10.e4" /><pair ddi="false" e1="DDI-PubMed.19130187.s10.e4" e2="DDI-PubMed.19130187.s10.e0" /></sentence><sentence text="2 l/h) and MD (CL/F = 8"><entity charOffset="18-18" id="DDI-PubMed.19130187.s11.e0" text="F" /></sentence><sentence text="2 l/h)" /><sentence text=" For MDZ, only MONOLIX was able to estimate CL/F and to provide its standard error of estimation with MD"><entity charOffset="1-1" id="DDI-PubMed.19130187.s13.e0" text="F" /><entity charOffset="47-47" id="DDI-PubMed.19130187.s13.e1" text="F" /><pair ddi="false" e1="DDI-PubMed.19130187.s13.e0" e2="DDI-PubMed.19130187.s13.e0" /><pair ddi="false" e1="DDI-PubMed.19130187.s13.e0" e2="DDI-PubMed.19130187.s13.e1" /></sentence><sentence text=" With MONOLIX, whatever the design and the administration setting, MDZ CL/F was well estimated and there were no statistical differences between CL/F estimated values obtained with FD (72 l/h and 40 l/h for MDZ alone and for MDZ with SX, respectively) and MD (77 l/h and 45 l/h for MDZ alone and for MDZ with SX, respectively)"><entity charOffset="148-149" id="DDI-PubMed.19130187.s14.e0" text="F" /><entity charOffset="309-311" id="DDI-PubMed.19130187.s14.e1" text="SX" /><entity charOffset="74-75" id="DDI-PubMed.19130187.s14.e2" text="F" /><entity charOffset="181-182" id="DDI-PubMed.19130187.s14.e3" text="F" /><entity charOffset="234-235" id="DDI-PubMed.19130187.s14.e4" text="SX" /><pair ddi="false" e1="DDI-PubMed.19130187.s14.e2" e2="DDI-PubMed.19130187.s14.e2" /><pair ddi="false" e1="DDI-PubMed.19130187.s14.e2" e2="DDI-PubMed.19130187.s14.e0" /><pair ddi="false" e1="DDI-PubMed.19130187.s14.e2" e2="DDI-PubMed.19130187.s14.e3" /><pair ddi="false" e1="DDI-PubMed.19130187.s14.e2" e2="DDI-PubMed.19130187.s14.e4" /><pair ddi="false" e1="DDI-PubMed.19130187.s14.e2" e2="DDI-PubMed.19130187.s14.e1" /><pair ddi="false" e1="DDI-PubMed.19130187.s14.e0" e2="DDI-PubMed.19130187.s14.e0" /><pair ddi="false" e1="DDI-PubMed.19130187.s14.e0" e2="DDI-PubMed.19130187.s14.e3" /><pair ddi="false" e1="DDI-PubMed.19130187.s14.e0" e2="DDI-PubMed.19130187.s14.e4" /><pair ddi="false" e1="DDI-PubMed.19130187.s14.e0" e2="DDI-PubMed.19130187.s14.e1" /><pair ddi="false" e1="DDI-PubMed.19130187.s14.e3" e2="DDI-PubMed.19130187.s14.e3" /><pair ddi="false" e1="DDI-PubMed.19130187.s14.e3" e2="DDI-PubMed.19130187.s14.e4" /><pair ddi="false" e1="DDI-PubMed.19130187.s14.e3" e2="DDI-PubMed.19130187.s14.e1" /><pair ddi="false" e1="DDI-PubMed.19130187.s14.e4" e2="DDI-PubMed.19130187.s14.e4" /><pair ddi="false" e1="DDI-PubMed.19130187.s14.e4" e2="DDI-PubMed.19130187.s14.e1" /></sentence><sentence text=" Whatever the approach, NCA or population PK modelling, and for the latter approach, whatever the design, MD or FD, comparison tests showed that there was a statistical difference (P &lt; 0"><entity charOffset="112-113" id="DDI-PubMed.19130187.s15.e0" text="F" /></sentence><sentence text="0001) between individual MDZ log(AUC) obtained after MDZ administration alone and co-administered with SX"><entity charOffset="103-103" id="DDI-PubMed.19130187.s16.e0" text="SX" /></sentence><sentence text=" Regarding C(max), there was a statistical difference (P &lt; 0" /><sentence text="05) between individual MDZ log(C(max)) obtained under the 2 administration settings in all cases, except with the sparse design with MONOLIX" /><sentence text=" However, the effect on C(max) was small" /><sentence text=" Finally, SX was shown to be a moderate CYP3A4 inhibitor, which at therapeutic doses increased MDZ exposure by a factor of 2 in average and almost did not affect the C(max)"><entity charOffset="1-2" id="DDI-PubMed.19130187.s20.e0" text="F" /><entity charOffset="10-11" id="DDI-PubMed.19130187.s20.e1" text="SX" /><pair ddi="false" e1="DDI-PubMed.19130187.s20.e0" e2="DDI-PubMed.19130187.s20.e0" /><pair ddi="false" e1="DDI-PubMed.19130187.s20.e0" e2="DDI-PubMed.19130187.s20.e1" /></sentence><sentence text="" /><sentence text="The optimal sparse design enabled the estimation of CL/F of a CYP3A4 substrate and inhibitor when co-administered together and to show the interaction leading to the same conclusion as the full empirical design"><entity charOffset="55-56" id="DDI-PubMed.19130187.s22.e0" text="F" /></sentence><sentence text="" /></document>